129 related articles for article (PubMed ID: 21447795)
1. Focus issue: Rendering resistance futile.
Adler EM; Gough NR
Sci Signal; 2011 Mar; 4(166):eg3. PubMed ID: 21447795
[TBL] [Abstract][Full Text] [Related]
2. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
3. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
Xu W; Neckers L
Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
[No Abstract] [Full Text] [Related]
4. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
5. Potential role of the antiproliferative cytokine beta-galactoside binding protein in cancer therapy.
Mallucci L; Wells V
Curr Opin Investig Drugs; 2005 Dec; 6(12):1228-33. PubMed ID: 16370387
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.
Cheng H; Force T
Circ Res; 2010 Jan; 106(1):21-34. PubMed ID: 20056943
[TBL] [Abstract][Full Text] [Related]
7. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
[TBL] [Abstract][Full Text] [Related]
8. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
9. Upgrading gemcitabine with recycled kinase inhibitors.
Blanco FF; Pishvaian MJ; Brody JR
Cell Cycle; 2014; 13(18):2810-1. PubMed ID: 25486467
[No Abstract] [Full Text] [Related]
10. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
11. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death.
Singh S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):1-15. PubMed ID: 25143300
[TBL] [Abstract][Full Text] [Related]
12. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
Bagrodia S; Smeal T; Abraham RT
Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
[TBL] [Abstract][Full Text] [Related]
14. Focus issue: choreographing the dance of the mitotic kinases.
Gough NR
Sci Signal; 2011 Jun; 4(179):eg5. PubMed ID: 21712543
[TBL] [Abstract][Full Text] [Related]
15. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
17. The role of caspase-8 in resistance to cancer chemotherapy.
Kim PK; Mahidhara R; Seol DW
Drug Resist Updat; 2001 Oct; 4(5):293-6. PubMed ID: 11991682
[TBL] [Abstract][Full Text] [Related]
18. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
19. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
20. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
